Targeting NUDT21 siRNA drugs
Phase 1Small molecule
Targeting NUDT21 siRNA drugs is one of 33 small molecule programs targeting Retinoblastoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Retinoblastoma
#DrugCompanyPhaseTrials
1Paraplatin
AAvyxa
Phase 3
Tepadina
Alnylam PharmaceuticalsPhase 3
Vepesid
AAvyxa
Phase 3
Alkeran
AApotex Inc.
Phase 3
Oncovin
EEastern Cooperative Oncology Group
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Hycamtin
MMeitheal
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Oncovin
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details